Hunan Warrant Pharmaceutical Co., Ltd., established in 2001 and listed on the Shanghai Stock Exchange STAR Market in 2021, is a leading innovation-driven pharmaceutical manufacturer headquartered in Changsha, China. The company operates a comprehensive industrial chain that integrates R&D, production, and sales across chemical medicines, traditional Chinese medicine (TCM), and biological macromolecules. With a workforce of over 1,000 employees and an annual revenue reaching approximately CNY 950 million, the company maintains three GMP-certified manufacturing factories and three specialized R&D institutes. Hunan Warrant Pharmaceutical specializes in a diverse portfolio including Active Pharmaceutical Ingredients (APIs), pharmaceutical excipients, intermediates, and finished drug preparations. Key API products include Mycophenolate Mofetil, Fosfomycin Trometamol, Entecavir, Ticagrelor, and Pantoprazole Sodium. Their herbal extract division focuses on high-purity standardized production of Ivy Leaf, Green Tea, and Ginkgo Biloba extracts, serving the health products, cosmetics, and feed additive industries. As a vertically integrated provider, the company offers OEM, ODM, and contract manufacturing (CMO/CRO) services. Their commitment to quality is evidenced by GMP certifications and drug production licenses (DML), supporting their competitive presence in both domestic and international pharmaceutical markets.